GIPR is involved in insulin release and glycemic control. Rival drugs from Eli Lilly and Viking Therapeutics also target GIPR, but they mimic it. Renza noted the placebo group had a higher bone ...
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Eli Lilly’s CEO, Dave Ricks, has been named the recipient of ... Start by taking a quick retirement quiz from SmartAsset that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback